Juan Sanchez - Intra Cellular President
| ITCIDelisted Stock | USD 131.87 0.03 0.02% |
President
Dr. Juan F. Sanchez, M.D., is Vice President Corporationrationrate Communications of IntraCellular Therapies, Inc. Previously, he was a healthcare research analyst at investment banking firm Ladenburg Thalmann Co. Inc., with a deep focus on companies specializing in central nervous system diseases from 2008 to 2014, most recently as a Managing Director. Prior to that time, he was a Vice President of healthcare and nanotechnology equity research at investment banking firm Punk, Ziegel, Co. Dr. Sanchez received his Master in International Affairs from Columbia University and his MBA from University of Los Andes in Bogota, Colombia. Dr. Sanchez practiced medicine for five years in his native country, Colombia, having received a medical degree from Pontifical Xavierian University, in Bogota. since 2014.
| Age | 53 |
| Tenure | 11 years |
| Phone | 646 440 9333 |
| Web | https://www.intracellulartherapies.com |
Intra Cellular Management Efficiency
The company has return on total asset (ROA) of (0.0696) % which means that it has lost $0.0696 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0858) %, meaning that it created substantial loss on money invested by shareholders. Intra Cellular's management efficiency ratios could be used to measure how well Intra Cellular manages its routine affairs as well as how well it operates its assets and liabilities.Intra Cellular Therapies currently holds 16.98 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Intra Cellular Therapies has a current ratio of 9.61, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Intra Cellular's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 7 records | PRESIDENT Age | ||
| Erin Lanciani | Sage Therapeutic | 55 | |
| David Gaffin | Alkermes Plc | 52 | |
| Amy Schacterle | Sage Therapeutic | N/A | |
| Meredith Kaya | Apellis Pharmaceuticals | N/A | |
| Michael Landine | Alkermes Plc | 70 | |
| Gregory Divis | Avadel Pharmaceuticals PLC | 58 | |
| Victoria Brown | Apellis Pharmaceuticals | 45 | |
Management Performance
| Return On Equity | -0.0858 | |||
| Return On Asset | -0.0696 |
Intra Cellular Therapies Leadership Team
Elected by the shareholders, the Intra Cellular's board of directors comprises two types of representatives: Intra Cellular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intra. The board's role is to monitor Intra Cellular's management team and ensure that shareholders' interests are well served. Intra Cellular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intra Cellular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO, Fin | ||
| Juan MD, Vice Relations | ||
| Robert Davis, Senior Vice President and Chief Scientific Officer | ||
| Michael PharmD, Senior Affairs | ||
| Suresh MD, Executive Officer | ||
| Mark Neumann, Executive Vice President Chief Commercial Officer | ||
| Karen Esq, Senior Officer | ||
| Willie MD, Senior Development | ||
| Sharon Mates, Co-Founder, Chairman, CEO and Pres | ||
| Michael JD, General VP | ||
| Sanjeev Narula, Executive CFO | ||
| Juan Sanchez, Vice President - Corporate Communications and Investor Relations | ||
| John Bardi, Senior Vice President - Market Access, Policy and Government Affairs | ||
| Lawrence CPA, CFO, Finance | ||
| John Condon, General President | ||
| Michael Olchaskey, Senior Vice President Head of Regulatory Affairs |
Intra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intra Cellular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0858 | |||
| Return On Asset | -0.0696 | |||
| Profit Margin | (0.11) % | |||
| Operating Margin | (0.15) % | |||
| Current Valuation | 13.06 B | |||
| Shares Outstanding | 106.52 M | |||
| Shares Owned By Insiders | 2.48 % | |||
| Shares Owned By Institutions | 96.40 % | |||
| Number Of Shares Shorted | 2.67 M | |||
| Price To Earning | (6.56) X |
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Intra Stock
If you are still planning to invest in Intra Cellular Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intra Cellular's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |